Who
Mark Fishman
Director
Company insider
Files Form 4 as: Director, Beam Therapeutics.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 10 Feb 2020
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,676 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,676 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —33,662 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —23,114 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —16,532 at $0.00 | filing |
| 1 Sep 2022filed 2 Sep 2022 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —10,391 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —6,877 at $0.00 | filing |
| 10 Feb 2020filed 11 Feb 2020 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code C | —15,768 | filing |
| 10 Feb 2020filed 11 Feb 2020 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code C | —1,239 | filing |
| 10 Feb 2020filed 11 Feb 2020 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code C | —17,007 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.